Schizophrenia for Eating - Bathing and Dressing -myassignmenthelp

Question: Discuss about theSchizophrenia for Eating, Bathing and Dressing. Answer: Schizophrenia is a severe mental and chronic disorder that affects the thinking, feeling and behaviour of an individual. The patients with schizophrenia seem to lose touch with reality. Schizophrenia is a neuropsychiatric disorder that affects the three main areas: two areas in the frontal lobe and CA1 area in the hippocampus that comprises of a small region. Although it is not a terribly common disease, it is a severe one. Globally, about 1% of the population is diagnosed with this disease mainly 1.2% (3.2 million) suffer from schizophrenia (Farmer Chapman, 2016). The lifetime prevalence of schizophrenia is 0.87% and incidence is 15.2 in 100,000 persons that show prominent variation. Epidemiological studies show that lifetime prevalence is around 1% according to National Institute for Mental Health, 2015 (National Institute for Mental Health (2015). In a recent Singapore study on mental health, Multi-Disciplinary Team (MDT) is required for care delivery by different healthcare prof essionals in providing care to the schizophrenic patients. Therefore, the following assignment will discuss the development of MDT, identification of interventions in providing best care while working with clients suffering from mental health conditions in Singapore. Schizophrenia is a severe and challenging disorder in which a person is unable to distinguish between unreal and real, clearly think, manage motions and function normally. There is fear, confusion experienced in schizophrenic patients and seem to withdraw from the social world. There is also disruption of normal daily activities like eating, bathing, dressing or running errands. Schizophrenia is likely to develop more in males than females at an earlier age between 16 and 25 years and average onset age is 25 in women and 18 in men. The peak onset of the disease in males is 20-28 years and in females, 26-32 years (Chong et al., 2017). The onset is rare in childhood as compared to middle or older age groups. According to World Health Organization (WHO), schizophrenia affects more than 21 million people globally; however, it is not common as compared to other mental health disorders (World Health Organization, 2010). There is stigmatization, discrimination and violation of rights of peo ple living with schizophrenia. Schizophrenia is a clinical diagnosis that is differentiated from other medical illnesses where there is requirement of integration of medical, psychosocial and psychological inputs carried out by MDT. Antipsychotic medications help in the prevention of relapses or in diminishing the positive schizophrenic symptoms. The exact etiology of schizophrenia is still unknown. However, research suggests that it is a combination of causes including genetics and environmental factors. According to Ripke et al., (2013) the genomic experiments suggest that schizophrenia is mainly associated with SNPs with alleles and uncommon copy number variations (mainly deletions). Recently, researchers have identified a gene named C4 or complement component 4 that is involved in immune system that increases the risk of the mental illness (Sekar et al., 2016). After the conduction of tests in mice and humans, this identified gene is involved in the elimination of connections between neurons called synaptic pruning. The strongest genetic predictor that increases schizophrenia risk is located on chromosome 6 on DNA (Ripke et al., 2014). According to Reichenberg et al., (2016) although genetic factors are involved in the disease etiology, environment also plays an important role in the development of the illness affecting gene expression. In the early life, factors like maternal nutrition, obstetric complications, maternal stress and postnatal or prenatal infections increases the risk of schizophrenia as proposed by EU-GEI, 2014. In the later life, drug abuse, ethnicity or migration, social adversity, urbanization is also the environmental factors that might increase the risk of this illness. The contributing factors that increases schizophrenia risk has a great impact on the life of the people suffering from the disease. It affects their everyday life and overall quality of life. It is troublesome to life alteration that affects personal, professional and social life. There is tendency of the individuals to withdraw themselves from others and exhibit mood behaviors that are inappropriate making relationships difficu lt. Symptoms associated with the disease like delusions or hallucinations hinder them from participating their family chores and social life. There is also reduced physical performance due to worsening of physical health exacerbating Activities of Daily Living (ADL) disability (Patel et al., 2014). The resultant impairments are witnessed across ADL from basic activities to mobility and job skills. Concisely, schizophrenia has a potential impact on the motor abilities, cognition and physical capacity hampering overall quality of life. Schizophrenia is a complex disorder that involves the multiple pathways dysregulation where dopaminergic, GABAergic and glutamatergic neurotransmitter are affected. Anatomic, immune system and neurotransmitter abnormalities have implications on the schizophrenia pathophysiology. There is identification of deficits in the acetylcholine muscarinic receptors where inflammation has been found to be the major contributor to the development, exacerbation of schizophrenia. Neuroimaging studies shows that there is decrease in brain volume, enlarged ventricles in the medial temporal areas along with changes witnessed in hippocampus. Anatomic abnormalities are seen in the limbic and neocortical regions and in the interconnection of white-matter tracts that are reduced in the brains of schizophrenic patients. There are abnormalities seen in the dopaminergic systems exhibiting hypodopaminergic activity in mesocortical system that leads to negative symptoms and hyperdopaminergic activity that lead to positive symptoms (Jenkins, 2013). There is also over activation and disturbance in the immune system that may result in inflammatory cytokines over expression and alteration in function and structure of brain. For example, elevated proinflammatory cytokine level activates kynurenine pathway where tryptophan is metabolized into quinolinic and kynurenic acids. These acids cause regulation of NMDA receptor activity involved in the regulation of dopamine. Metabolic disturbances and insulin resistance are common in schizophrenia linked to inflammation (Lee et al., 2014). Therefore, inflammation may be related to the schizophrenia psychopathology and metabolic disturbances. The complications of schizophrenia are devastating as it affects the human emotion, thought and expression. There are only 20% of the full recovery chances after a first schizophrenic episode that improves their quality of life. Among the medical illnesses, diabetes occurs in schizophrenia as the anti-psychotic drugs elevate the blood sugar levels. In addition, depression is also common because of negative social impact common in the later adulthood. It also affects the social status, as there is decline in the inability to perform the ADLs and earn a living. The long-term effects include relationships and professional life that leads to social exclusion. Intelligence is also affected, as there is decline in IQ reflecting early nerve damage, however, it is not an inevitable cause for schizophrenia disease progression. Suicide is also a complication due to the frightening behavior and they tend to withdraw themselves from others or causes self-harm. An estimated, 9-14% of people commi t suicide out of 20-50% schizophrenic patients and behave violently as compared to the general population (Howes Murray, 2014). The above description shows that schizophrenia is a serious mental health problem that is occurring widely, frequently causing severe disability, and diminishing quality of life. There is high incidence and prevalence of schizophrenia worldwide that is contributing to the burden of disease. Schizophrenia is a psychotic condition that is affecting the overall quality of life indicating lower quality of life, loss of productivity, distress and secondary mental health problems like depression for the patients, their families and caregivers. Therefore, the above discussion shows that this mental health problem of schizophrenia is worth investigating and requires MDT approach for the care delivery to the patients. For the treatment of schizophrenia, MDT approach that integrates psychopharmacologist, therapist, physicians, clinical pharmacists, nurses being the valuable members of the team. This MDT comprises of consultant who would discuss the medical problems related to schizophrenia along with prescribed medication. The psychiatrist would discuss the aspects of the illness so that the patient has a better look in overall life. The psychiatrist would discuss with the doctors and help in the recovery process for the clinical and social functioning of the schizophrenia patient. Social worker is also important who would encourage the patient for social integration and cope with environmental life aspects. Among this MDT, nurses play the most important role that provide all aspects of care in every phase of the disease in the psychiatric setting. Psychotherapist provides effective therapy for the best management of the unhealthy thinking in schizophrenia and develops new patterns that can help pa tient learn best ways to manage symptoms. The interventions are discussed in the next section. Antipsychotic treatment is the first pharmacological intervention that is used for the prevention of relapses and positive symptoms of schizophrenia (Kishimoto et al., 2013). Approximately, relapses occur within 1 year in around 80% of the patients if the medications are suddenly stopped. The choice of drug for schizophrenia treatment depends on the factors like cost, effectiveness, method of delivery, side-effect burden, tolerability and availability. The best choice of drug is the second-generation antipsychotics (SGAs), major tranquilizers or neuroleptic medications helps in diminishing the symptoms and in reducing the chances of relapses. SGAs have minimal extrapyramidal side effects (EP) as compared to the first generation counterparts. SGAs class of drugs includes clozapine, aripiprazole, iloperidone, olanzapine, risperidone, olanzapine, paliperidone. These class of drugs have prominent serotonin 5HT2A combined with D2 antagonism along with a unique receptor-binding profile for muscarinic, histamine and and serotonin receptors (Fonseka, Richter Mller, 2014). SGAs work principally by antagonizing or blocking the dopamine action at its receptors that in turn decreases the chemical signals that drives the violent or psychotic behaviour. The rationale for choosing this class of drugs is that EPS risk is less that are characterized by tremors, muscular rigidity, restlessness, shuffling movement and muscular spasms that result in abnormal posture (Nielsen et al., 2015). This new generation of antipsychotics are better tolerated and superior in the treatment of negative schizophrenic symptoms. It also reduces the tardive dyskinesia having more clinical efficacy in treatment-resistant schizophrenia. The areas of brain where cognition and emotion balance are affected by dopamine and serotonin; SGAs perform dual function to reset the balance when altered. Therefore, this class of drugs balances the disturbances in neurotransmitters that are manifested in schizophrenia being the best pharmacological treatment option. However, SGAs can cause side effects and bad interactions when used with other medications. It may cause uncontrollable movements like tremors, muscle spasms, weight gain, drowsiness, dizziness, restlessness, dry mouth, vomiting. The safe administration is important and among the MDT, nurses play the vital role in understanding the medication pharmacology, side effects and contraindications in a hospital setting. According to Divac et al., (2014) nurses lack in-depth knowledge about antipsychotics and fail to identify the potential adverse side effect of antipsychotics. Therefore, nurses have to consider parameters like patient safety, Extrapyramidal Syndromes, metabolic considerations, QTc Prolongation and Torsades de Pointes and employ patient education. Routine assessment of neurological status, ambulatory status and orthostatic vital signs is important for patient safety. Nurse should look for the EPS via early detection and look for serum glucose, weight, serum lipids and choles terol levels in the patient. Finally, for the safe use of drugs and reduce side effects, patient should be educated to look for the adverse effects and encourage them to continue with the prescribed medications. Another intervention is cognitive behavioural therapy (CBT) that treats the schizophrenia residual symptoms (both positive and negative types). CBT help the patients to learn them to live better, avoid relapse and reduction in certain symptoms. A psychotherapist helps the patient to change their perspectives of harmful or destructive beliefs and reduce suicidal ideation in an outpatient setting. The therapist helps the patient in transforming the negative or harmful cognitive patterns into positive and healthy beliefs (Subramaniam et al., 2012). The rationale for choosing CBT is that it helps patients to identify the triggering symptoms and handle their stresses and responsibilities better while living with the disease. The role of a psychotherapist is not to cure the disease, but to improve the functional ability of the person, independence, better management and reduction of stress that they experience in their daily life. Behavioural experiments, cognitive restructuring, coping sk ill training and self-monitoring are the CBT approaches that help patients to lead a normal life while living with the disease. Community services are also helpful that work in conjunction with the psychiatric care for the schizophrenic patients that minimize the social impact of the disease. Community-based mental health services provide full range of mental health care that are dedicated in the treatment and helping patients to relieve them from distress and enhance social inclusion. There is stigmatization and discrimination regarding mental health disorders and so, community care services emphasize on the improvement of quality of life, de-stigmatization of mental illness and promotion of self-sufficiency. Silver Ribbon in Singapore reaches out to the schizophrenic patients to help them build positive mental health. The community resources provide them an opportunity for the patients to reintegrate into the local community and help them lead a normal life. Singapore Association for Mental Health (SAMH), SACS that provide peer support, illness management and recovery program for schizophrenia. Club Heal ai ms to empower and assist schizophrenic patients to regain confidence and help them in community reintegration. National Council of Social Service provides support to schizophrenic patients for community integration by providing support services for seamless recovery. In Singapore, schizophrenia is the ninth leading cause of disability (2.7% since 2007, disability-adjusted life-years) and has been incorporated in the National Chronic Disease Management for the enhancement of patients care suffering from schizophrenia. It requires MDT approach for care delivery by different healthcare professionals in providing care to the schizophrenic patients. Researchers have identified a gene named C4 or complement component 4 that is involved in immune system that increases the risk of the mental illness. Antipsychotic treatment is the first pharmacological intervention and CBT improve the functional ability of the person, independence, better management and reduction of stress that they experience in their daily life. Community-based mental health services provide full range of mental health care for social inclusion and improve their quality of life. References Chong, S. A., Abdin, E., Vaingankar, J. A., Heng, D., Sherbourne, C., Yap, M., ... Subramaniam, M. (2017). A population-based survey of mental disorders in Singapore. Retrieved from: https://open-access.imh.com.sg/handle/123456789/4547 Divac, N., Prostran, M., Jakovcevski, I., Cerovac, N. (2014). Second-generation antipsychotics and extrapyramidal adverse effects.BioMed research international,2014. Doi: https://dx.doi.org/10.1155/2014/656370 European Network of National Networks studying Gene-Environment Interactions in Schizophrenia (EU-GEI. (2014). Identifying gene-environment interactions in schizophrenia: contemporary challenges for integrated, large-scale investigations.Schizophrenia bulletin,40(4), 729. Doi: 10.1093/schbul/sbu069 Farmer, R. F., Chapman, A. L. (2016).Behavioral activation. American Psychological Association. Fonseka, T. M., Richter, M. A., Mller, D. J. (2014). Second generation antipsychotic-induced obsessive-compulsive symptoms in schizophrenia: a review of the experimental literature.Current psychiatry reports,16(11), 510. Doi: 10.1007/s11920-014-0510-8 Howes, O. D., Murray, R. M. (2014). Schizophrenia: an integrated sociodevelopmental-cognitive model.The Lancet,383(9929), 1677-1687. Doi: https://doi.org/10.1016/S0140-6736(13)62036-X Jenkins, T. A. (2013). Perinatal complications and schizophrenia: involvement of the immune system.Frontiers in neuroscience,7. Doi: 10.3389/fnins.2013.00110 Kishimoto, T., Agarwal, V., Kishi, T., Leucht, S., Kane, J. M., Correll, C. U. (2013). Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics.Molecular psychiatry,18(1), 53. Doi: 10.1038/mp.2011.143 Lee, A. A., McKibbin, C. L., Bourassa, K. A., Wykes, T. L., Andren, K. A. K. (2014). Depression, diabetic complications and disability among persons with comorbid schizophrenia and type 2 diabetes.Psychosomatics,55(4), 343-351.Doi: https://doi.org/10.1016/j.psym.2013.12.015 National Institute for Mental Health (2015) Schizophrenia homepage. Retrieved 15 June 2015, from: https://www.nimh.nih.gov/health/topics/schizophrenia/index.shtml Nielsen, R. E., Levander, S., Kjaersdam Telleus, G., Jensen, S. O. W., stergaard Christensen, T., Leucht, S. (2015). Second?generation antipsychotic effect on cognition in patients with schizophreniaa meta?analysis of randomized clinical trials.Acta Psychiatrica Scandinavica,131(3), 185-196. Doi: 10.1111/acps.12374 Patel, R., Jayatilleke, N., Jackson, R., Shetty, H., Stewart, R., McGuire, P. (2014). Poster# S170 Identifying Negative Symptoms In Schizophrenia And Association With Clinical Outcomes Using Natural Language Processing.Schizophrenia Research,153, S151.Doi: https://dx.doi.org/10.1016/S0920-9964(14)70449-9 Reichenberg, A., Cederlf, M., McMillan, A., Trzaskowski, M., Kapara, O., Fruchter, E., ... Plomin, R. (2016). Discontinuity in the genetic and environmental causes of the intellectual disability spectrum.Proceedings of the National Academy of sciences,113(4), 1098-1103. Doi: 10.1073/pnas.1508093112 Ripke, S., Neale, B. M., Corvin, A., Walters, J. T., Farh, K. H., Holmans, P. A., ... Pers, T. H. (2014). Biological insights from 108 schizophrenia-associated genetic loci.Nature,511(7510), 421. Doi:10.1038/nature13595 Ripke, S., O'Dushlaine, C., Chambert, K., Moran, J. L., Khler, A. K., Akterin, S., ... Kim, Y. (2013). Genome-wide association analysis identifies 13 new risk loci for schizophrenia.Nature genetics,45(10), 1150-1159. doi:10.1038/ng.2742 Sekar, A., Bialas, A. R., de Rivera, H., Davis, A., Hammond, T. R., Kamitaki, N., ... Genovese, G. (2016). Schizophrenia risk from complex variation of complement component 4.Nature,530(7589), 177. Doi: 10.1038/nature16549 Subramaniam, M., Vaingankar, J., Heng, D., Kwok, K. W., Lim, Y. W., Yap, M., Chong, S. A. (2012). The Singapore Mental Health Study: an overview of the methodology.International Journal of Methods in Psychiatric Research,21(2), 149-157. Doi: 10.1002/mpr.1351 World Health Organisation (2010). International Statistical Classification of Diseases and Related Health Problems 10th Revision version 2010. Retrieved June 20, 2012 from https://apps.who.int/classifications/icd10/browse/2010/en#/